Training & Resources

Accessing evidence-based, up-to-date resources can equip you to offer your patients the best care and guidance throughout their treatment journey. From case studies, videos and more, explore a wealth of curated resources designed to help you better support patients.

Therapy area
Lung cancer
Non-small cell lung cancer
Lymphoma
Cutaneous T-cell lymphoma
Hodgkin lymphoma
Peripheral T-cell lymphoma
Multiple Myeloma
Resource type
Expert on Demand
Other resources
Videos and podcasts
Sort by: Most recent
Sort by: Popularity
Sort by: Title
Appropriate Sequencing_Ahmed
Prescribing information Alunbrig
ALUNBRIG® (brigatinib) Expert Opinion Video Series: Appropriate sequencing of ALK TKI therapies in ALK+ aNSCLC in England

Listen to Prof Samreen Ahmed explore the funded ALK TKI treatment options available for ALK+ aNSCLC in England as per NICE TA, CDF and NHS England Blueteq eligibility criteria. 

QOL_Summers
Prescribing information Alunbrig
ALUNBRIG® (brigatinib) Expert Opinion Video Series: Impact of brain metastases on patients with ALK+ aNSCLC and ALUNBRIG quality of life (QOL) data from the ALTA-1L study

Listen to Dr Yvonne Summers discuss the current unmet needs of patients with ALK+ aNSCLC, including the negative impact of brain metastases on the daily lives of these patients. 

Dr Summers provides an overview of the ALUNBRIG health-related QOL data from the ALTA-1L study in patients with ALK+ aNSCLC and how these results compare with her real-world experience in clinical practice. 

Initiating Patient_Clark
Prescribing information Alunbrig
ALUNBRIG® (brigatinib) Expert Opinion Video Series: Initiating patients on ALUNBRIG

Listen to Dr Brian Clark share his experience of initiating ALUNBRIG in patients with ALK+ aNSCLC to gain insight that can be translated into your own clinical practice. 

Dr Clark discusses the recommended ALUNBRIG dosing regimen, and highlights the availability of the starter pack and provision of the patient alert card for your patients with ALK+ aNSCLC.

 

Managing Toxicities_Ghosh
Prescribing information Alunbrig
ALUNBRIG® (brigatinib) Expert Opinion Video Series: Managing toxicities and side effects associated with ALUNBRIG

Listen to Dr Sharmistha Ghosh who shares her experience on the management of patients with ALK+ aNSCLC during treatment with ALUNBRIG, including the specific monitoring required. 

Jackson_Lenalidomide Rechallenge
Prescribing information Ninlaro
How can we determine whether lenalidomide rechallenge is an option for patients with RRMM?

Lenalidomide has become an integral part of first-line treatment in patients with multiple myeloma.1 As patients progress to later lines, options can become limited, and the choice of treatment offered in patients who relapse should be carefully evaluated.2 Defining and understanding the lenalidomide status of patients with multiple myeloma can help guide the next line of treatment and which patients can be rechallenged appropriately with lenalidomide post relapse.